Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Mizuho Analyst Says

Amylyx Pharmaceuticals (NASDAQ:AMLX) had its target price increased by investment analysts at Mizuho from $21.00 to $24.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price objective suggests a potential upside of 35.21% from the stock’s current price.

AMLX has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, May 8th. Guggenheim lifted their price target on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, June 25th. Wall Street Zen downgraded Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Amylyx Pharmaceuticals in a report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.62.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $17.75 on Monday. The company’s fifty day moving average price is $15.51 and its two-hundred day moving average price is $14.97. The firm has a market capitalization of $1.97 billion, a P/E ratio of -11.83 and a beta of -0.20. Amylyx Pharmaceuticals has a 12 month low of $7.48 and a 12 month high of $19.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, sell-side analysts anticipate that Amylyx Pharmaceuticals will post -1.4 EPS for the current year.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the sale, the insider directly owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.90% of the company’s stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in AMLX. Landscape Capital Management L.L.C. boosted its holdings in shares of Amylyx Pharmaceuticals by 17.5% in the fourth quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock valued at $148,000 after purchasing an additional 1,825 shares during the period. KBC Group NV bought a new stake in Amylyx Pharmaceuticals during the 1st quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. raised its position in Amylyx Pharmaceuticals by 54.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock valued at $64,000 after purchasing an additional 1,890 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth $25,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Amylyx Pharmaceuticals by 14.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,895 shares of the company’s stock worth $216,000 after buying an additional 2,265 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.